[1]
|
Scappaticcio, L., et al. (2021) Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid, 31, 884-894. https://doi.org/10.1089/thy.2020.0715
|
[2]
|
Newsome, P.N., et al. (2018) Guidelines on the Management of Abnormal Liver Blood Tests. Gut, 67, 6-19.
https://doi.org/10.1136/gutjnl-2017-314924
|
[3]
|
Lin, T.Y., et al. (2017) Incidence of Abnormal Liver Biochemical Tests in Hyperthyroidism. Clinical Endocrinology (Oxford), 86, 755-759. https://doi.org/10.1111/cen.13312
|
[4]
|
Wang, R., Tan, J., Zhang, G., Zheng, W. and Li, C. (2017) Risk Factors of Hepatic Dysfunction in Patients with Graves’ Hyperthyroidism and the Efficacy of 131 Iodine Treatment. Medicine (Bal-timore), 96, e6035.
https://doi.org/10.1097/MD.0000000000006035
|
[5]
|
Li, C., et al. (2015) Risk Factors of Hyperthyroidism with Hepatic Function Injury: A 4-Year Retrospective Study. Hormone and Metabolic Research, 47, 209-213. https://doi.org/10.1055/s-0034-1375690
|
[6]
|
Ruiz, J.K., et al. (2003) Fulminant Hepatic Failure Associated with Propylthiouracil. Annals of Pharmacotherapy, 37, 224-228. https://doi.org/10.1177/106002800303700213
|
[7]
|
Khemichian, S. and Fong, T.L. (2011) Hepatic Dysfunction in Hyperthyroidism. Gastroenterology & Hepatology (NY), 7, 337-339.
|
[8]
|
Pasyechko, N.V., et al. (2017) Ultrastructur-al Liver Changes in the Experimental Thyrotoxicosis. Polish Journal of Pathology, 68, 144-147. https://doi.org/10.5114/pjp.2017.69690
|
[9]
|
Huang, P.S., Wang, C.S., Yeh, C.T. and Lin, K.H. (2019) Roles of Thyroid Hormone-Associated microRNAs Affecting Oxidative Stress in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 20, 5220.
https://doi.org/10.3390/ijms20205220
|
[10]
|
杨月莲. 甲亢合并肝损害的研究进展[J]. 中国医药指南, 2020, 18(11): 30-32, 37.
|
[11]
|
黄子锐. Graves病合并甲亢性肝损害的临床诊疗研究进展[J]. 现代医药卫生, 2020, 36(12): 1848-1850.
|
[12]
|
李舒祺, 张海清. 甲状腺功能异常相关性肝损害研究进展[J]. 中国实用内科杂志, 2022, 42(2): 164-167.
|
[13]
|
de Campos Mazo, D.F., et al. (2013) Clinical Spectrum and Therapeutic Approach to Hepatocel-lular Injury in Patients with Hyperthyroidism. Clinical and Experimental Gastroenterology, 6, 9-17. https://doi.org/10.2147/CEG.S39358
|
[14]
|
Venediktova, N.I., Mashchenko, O.V., Talanov, E.Y., Belosludtseva, N.V. and Mironova, G.D. (2020) Energy Metabolism and Oxidative Status of Rat Liver Mitochondria in Conditions of Experimentally Induced Hyperthyroidism. Mitochondrion, 52, 190-196. https://doi.org/10.1016/j.mito.2020.04.005
|
[15]
|
Upadhyay, G., et al. (2004) Severe Hyperthyroidism Induces Mi-tochondria-Mediated Apoptosis in Rat Liver. Hepatology, 39, 1120-1130. https://doi.org/10.1002/hep.20085
|
[16]
|
卢亚敏, 张明明. CD4+CD25+调节性T细胞及细胞因子在甲亢性肝损害发生中的作用[J]. 实用医学杂志, 2014(19): 3126-3128.
|
[17]
|
Boelaert, K., et al. (2010) Prevalence and Relative Risk of Other Autoimmune Diseases in Subjects with Autoimmune Thyroid Disease. The American Journal of Medicine, 123, 183e181-189. https://doi.org/10.1016/j.amjmed.2009.06.030
|
[18]
|
He, K., Hu, Y., Xu, X.H. and Mao, X.M. (2014) Hepatic Dys-function Related to Thyrotropin Receptor Antibody in Patients with Graves’ Disease. Experimental and Clinical Endo-crinology and Diabetes, 122, 368-372.
https://doi.org/10.1055/s-0034-1375667
|
[19]
|
马学芹, 等. 甲亢性肝损害与IL-23/Th17轴细胞因子的相关性研究[J]. 免疫学杂志, 2013, 29(2): 152-155.
|
[20]
|
Zhang, Q., et al. (2018) RNASET2, GPR174, and PTPN22 Gene Polymorphisms Are Related to the Risk of Liver Damage Associated with the Hyperthyroidism in Patients with Graves’ Disease. Journal of Clinical Laboratory Analysis, 32, e22258. https://doi.org/10.1002/jcla.22258
|
[21]
|
Wafa, B., Faten, H., Mouna, E., Fatma, M. and Mohamed, A. (2020) Hyperthyroidism and Hepatic Dysfunction: Report of 17 Cases. JGH Open, 4, 876-879. https://doi.org/10.1002/jgh3.12337
|
[22]
|
Piantanida, E., et al. (2020) The Interplay between Thyroid and Liver: Implications for Clinical Practice. Journal of Endocrinological Investigation, 43, 885-899. https://doi.org/10.1007/s40618-020-01208-6
|
[23]
|
Suzuki, N., et al. (2019) Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves’ Disease in Japan. Thyroid, 29, 1390-1398. https://doi.org/10.1089/thy.2019.0045
|
[24]
|
段然, 李静. 甲状腺功能亢进症合并肝损害的鉴别诊断和处理[J]. 中国实用内科杂志, 2018, 38(10): 971-973.
|
[25]
|
施秉银. 甲状腺功能亢进症伴抗甲状腺药物所致肝损伤的识别与处理[J]. 中国实用内科杂志(临床版), 2006, 26(9): 654-656.
|
[26]
|
Primeggia, J. and Lewis, J.H. (2010) Gone (from the Physicians’ Desk Reference) but Not Forgotten: Propylthiouracil- Associated Hepatic Failure: A Call for Liver Test Monitoring. Journal of the National Medical Association, 102, 531-534.
https://doi.org/10.1016/S0027-9684(15)30564-2
|
[27]
|
蒋宁一, 等. 131I治疗Graves甲亢专家共识(2010年) [J]. 国际内分泌代谢杂志, 2012, 32(2): 138-144.
|
[28]
|
邢家骝. 131I治疗甲状腺功能亢进症的进展[J]. 中华老年多器官疾病杂志, 2013, 12(2): 94-97.
|
[29]
|
蔡敏, 等. 131I对Graves病患者甲状腺细胞凋亡的影响[J]. 中华核医学杂志, 2011, 31(1): 54-57.
|
[30]
|
Chawla, M. and Bal, C.S. (2008) Four Cases of Coexistent Thyrotoxicosis and Jaundice: Results of Radioiodine Treatment and a Brief Review. Thyroid, 18, 289-292. https://doi.org/10.1089/thy.2007.0123
|
[31]
|
邢家骝, 丁勇, 方毅. (131)Ⅰ治疗甲状腺功能亢进症的进展[J]. 中华内分泌代谢杂志, 2010, 26(4): 265-268.
|
[32]
|
邱明才. 甲状腺功能亢进症治疗的反思[J]. 中华医学杂志, 2002(3): 7-8.
|
[33]
|
王家丽, 周蓉, 万明, 田培志. 甲基强的松龙成功治疗重症Graves病伴肝损害(附4例临床分析) [J]. 华西医学, 2007, 22(4): 847-847.
|
[34]
|
Hasan, M.K., Tierney, W.M. and Baker, M.Z. (2004) Severe Cholestatic Jaundice in Hyperthyroidism after Treatment with 131-Iodine. The American Journal of the Medical Sciences, 328, 348-350.
https://doi.org/10.1016/S0002-9629(15)33945-8
|
[35]
|
Haddaden, M., et al. (2021) Cholestatic Hepatitis in Graves’ Disease: A Diagnostic Challenge. ACG Case Reports Journal, 8, e00526. https://doi.org/10.14309/crj.0000000000000526
|
[36]
|
裴玲琪. 甲状腺功能亢进症合并肝损伤的病因诊断及治疗进展[J]. 海南医学, 2022, 33(7): 922-925.
|
[37]
|
闫瑞红, 周振虎, 张玉芳, 左书耀. 131I与131I联合保肝药物治疗Graves甲亢合并肝损害的疗效比较[J]. 中华核医学与分子影像杂志, 2012, 32(4): 269-272.
|
[38]
|
陆永经, 莫海花, 邱志兴. 比较131I及131I联合保肝药物治疗Graves甲状腺功能亢进症合并肝功能损害的效果分析[J]. 中国医药指南, 2014(8): 49.
|